Our findings concur with the observations of Branford and others that the rate of BCR::ABL1 decline can serve as a critical prognostic discriminator of CML patients after the first 3 months of TKI treatment [10]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.